Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication
Key facts
- Who runs it
- Xijing Hospital of Digestive Diseases
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 558 people enrolled
- Started
- 20 Sept 2024
- Ended
- 25 Jun 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Berberine
- Vonoprazan
- Amoxicillin
- Bismuth
- Clarithromycin
- Esomeprazole
- Record updated
- 3 July 2025
Who can take part
- Age
- 17 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (20)Hide the full registry criteria
Who can take part
- Age between 18~70,both gender
- Patients with upper gastrointestinal symptoms and with documented H.pylori infection who did not receive Helicobacter pylori eradication treatment
- Patients are willing to receive eradication treatment
- Women of childbearing age were required to use medically acceptable contraceptive methods during and 30 days after the trial
Who cannot take part
- Patients are excluded if they have previously used antibiotics to eradicate adequately recorded infection with H. pylori
- Constant use of anti-ulcer drugs ( including taking proton-pump.inhibitors(PPI) within 2 weeks before the [13C] urea breath test),antibiotics or bismuth complexes (more than 3 times /1 month before screening)
- Underwent upper gastrointestinal Surgery
- Drug or alcohol abuse history in the past 1 year
- Patients with contraindications or allergies to the study drug
- Severe organ damage and complications (such as liver cirrhosis, uremia, etc.), severe or unstable cardiopulmonary or endocrine diseases
- Patients were diagnosed with gastroduodenal ulcer and MALTlymphoma
- Evidence of bleeding or iron efficiency anemia
- A history of malignancy
- Systemic use of corticosteroids, non steroidal anti-inflammatory drugs,anticoagulants, platelet aggregation inhibitors (except the use of aspirin for less than 100 mg/d)
- Pregnant or lactating women
- Patients with moderate to severe dysplasia or high degree of intraepithelial neoplasia
- Patients have symptom of dysphagia
- Patients who has psychological problem or poor compliance
- Enrolled in other clinical trials in the past 3 months
- Refuse to sign informed consent
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study was to evaluate the efficacy and safety of the triple therapy of berberine hydrochloride, vonorasan and amoxicillin for the primary eradication of Helicobacter pylori.It is hypothesized that berberine hydrochloride, amoxicillin and vonoprazan triple therapy is non-inferior to bismuth-containing quadruple therapy.Patients diagnosed with H. pylori infection will be randomly divided into one of the above treatments. At week 6 follow-up visits, a urea breath test,rapid urease test or helicobacter pylori stool antigen test will be performed to confirm eradication.
The 2 groups in the trial
- Berberine-containing triple therapyTreatment being tested
vonoprazan 20 mg , amoxicillin 1000 mg , and berberine 500 mg by mouth,twice daily for 14 days.
Treatment: Berberine, Vonoprazan, and Amoxicillin
- Bismuth-containing quadruple therapyExisting treatment, for comparison
Bismuth potassium citrate 220 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
Treatment: Amoxicillin, Bismuth, Clarithromycin, and Esomeprazole
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Study on The Efficacy and Safety of Berberine,Amoxicillin and Vonoprazan Containing Triple Therapy in Helicobacter Pylori First-Line Eradication
- Record updated
- 3 July 2025